The history of the erectile dysfunction drug presents a challenging picture for investors. While the initial launch generated significant gains, the expiration of its patent opened the avenue to off-brand alternatives, https://alvingniz662048.csublogs.com/49734636/the-copyright-and-big-pharma-a-precarious-bet